Acquisition allows Pace® to provide full-service regulatory strategy and consulting services to advance FDA submissions across a wide range of […]
First Wave BioPharma Chooses Pace® Life Sciences as CDMO Partner. BOCA RATON, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) — First
Research involves microgranule delivery formulations for adrulipase BOCA RATON, Fla., Aug. 31, 2022 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc.,
Acquisition allows Pace® to provide regulatory and quality consulting services to support clients throughout the drug development process and improve
Company excels in Labor & Human Rights and Ethics performance for current Corporate Social Responsibility (CSR) Initiatives. Pace® Life Sciences,
Pharmaceutical Technology hosts “The Evolution of an NCE’s Suspension Formulation, from pre-GLP Studies to the Pharmacy Shelf” – a webinar
Frank Tagliaferri, Ph.D., Vice President of Pharmaceutical Development sat down with BioProcess International to discuss the growth the industry, and
Frank Tagliaferri, Ph.D., VP of Pharmaceutical Development & GM Biocompare, The Buyer’s Guide for Life Sciences Published an Article: The
Acquisition adds significant experience and expertise in the development of liquid, semi-solid, and oral solid dose products for pre-clinical and clinical use
Acquisition allows Pace to support a growing number of clients requiring services throughout the drug development process while adding expertise
